Enjoy complimentary customisation on priority with our Enterprise License!
The breast biopsy devices market size is forecast to increase by USD 778.7 million at a CAGR of 10.87% between 2024 and 2028. Market growth is driven by the rise in breast cancer cases, growing focus on women's health diagnostics, increased regulatory approvals, and mergers and acquisitions in the healthcare sector. These factors enhance innovation, expand market reach, and improve early detection and treatment efficacy.
For More Highlights About this Report, Request Free Sample
The field of breast cancer care is advancing through various platforms like conferences and webinar materials that disseminate crucial information on breast cancer screening, diagnosis, and treatment. With a focus on improving outcomes, reimbursements play a pivotal role in ensuring treatment accessibility across surgical centers, hospitals, and research laboratories. As the incidence of breast cancer and related deaths caused by invasive breast cancers and premalignant breast conditions rise, screening procedures, including biopsy samples and breast cancer liquid biopsy testing devices are pivotal for early detection and therapy selection. Monitoring tools for treatment and recurrence are critical in both needle and surgical breast biopsy settings. Collaboration across pharmaceutical, biotechnology, and laboratory supplies sectors drives innovation in breast cancer care, aiming to enhance diagnosis accuracy and patient outcomes.
Increasing number of products showcasing and approvals is the key factor driving the growth of the market. Breast biopsies use a wide range of biopsy devices. The prominent vendors in the market are focusing on expanding and strengthening their product offerings for breast imaging technologies by obtaining approval from regulatory bodies for the commercialization of their products and showcasing these products at various conferences. Companies are showcasing their products to attract the attention of end-users and increase awareness about breast cancer screening.
Moreover, these companies are obtaining regulatory approvals, which can aid them in expanding their product portfolios. For example, Becton Dickinson and Co. offers BD EleVation Breast Biopsy System and EnCor Enspire Breast Biopsy System, which got approval from the United States Food and Drug Administration. The above factors will drive the market in focus during the forecast period.
Programs to detect breast cancer at the early stages is the primary trend in the market growth. Funding and grants offered by various government and private organizations are driving the development of new innovative products for the screening of breast cancer. These technologically advanced solutions are expected to aid in providing better solutions and technological tools and improve preventive care for patients. For instance, the European Commission has funded projects such as BRIDGES and B-CAST. BRIDGES is next-generation sequencing, which allows the identification of women who are at a high risk of breast cancer.
Moreover, this will help such high-risk patients to take adequate preventive action by undergoing a comprehensive evaluation of their DNA variations or mutations. B-CAST offers breast cancer stratification. These tools are being developed to allow the precise identification of the chances of breast cancer in people. Both projects are designed to improve current genetic testing approaches to determine the risk of developing breast cancer in women. This, in turn, will create opportunities for the growth of the global market during the forecast period.
The presence of alternative non-invasive procedures is a major challenge to the growth of the market. Core needle biopsy, FNA biopsy, and surgical biopsy are the most preferred methods of biopsy, which are recommended by physicians for the detection and identification of breast cancer in patients. In breast biopsy procedures, needles are inserted into the breast to take out sample tissues for further analysis. Surgical breast biopsies, which primarily involve the surgical removal of tissue from a lump or mass in the breast, are also commonly performed. The breast biopsy method recommended for and performed on patients primarily depends on the criticality of the situation of the patient. Special methods and guidance systems are used to perform the breast biopsy and aid in biopsy procedures. Various risks and complications, such as bruising, swelling, and infection at the site, are associated with breast biopsy procedures.
However, liquid biopsy is used as an alternative to core needle biopsy and surgical breast biopsy. Liquid biopsy is a simple and non-invasive process that allows the healthcare professional to obtain comprehensive information about the tumor through a blood sample analysis. This helps to prevent surgeries and monitor the progression of the disease. Human blood contains two types of cancer-derived materials, namely, intact circulating tumor cells (CTCs) and cell-free circulating tumor DNA (cfDNA, which is also referred to as circulating tumor DNA or ctDNA). Easy acceptance among patients, the non-invasive nature of the procedure, and quick results are the major factors driving the adoption of liquid breast biopsy by healthcare providers and patients. A liquid biopsy helps in the early detection of cancer. Increasing advances in liquid breast biopsy techniques are expected to increase their adoption by healthcare providers during the forecast period. The availability of alternative methods is one of the major challenges to the adoption of traditional breast biopsy techniques and devices to a certain extent. Hence, such factors are hindering the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
BIOPSYBELL Srl - The company offers breast biopsy devices and related products, such as Moon Needle, for the localization of breast lesions. The company manufactures medical equipment for surgeries such as assisted reproductive technology, ortho biologics, spine, and others.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth of the biopsy needles and systems segment will be significant during the forecast period. Needles are primarily used for collecting tissue from the suspicious areas of the breast during a biopsy. Needle biopsy is considered the gold standard procedure for breast biopsies. Core needle biopsy is a quick process that does not involve surgery. Owing to these factors, these needles are accepted by physicians for standard procedures.
Get a glance at the market share of various regions Download the PDF Sample
The biopsy needles and systems segment accounted for USD 402.40 million in 2018 and showed a gradual increase during the forecast period. Needle biopsy is considered the gold standard procedure for breast biopsies. Core needle biopsy is a quick process for breast biopsy, which does not involve surgery. Owing to these factors, breast biopsy needles are accepted by physicians for standard breast biopsy procedures. However, if the core needle biopsy is not guided by any guidance systems, such as MRI, ultrasound, and stereotactic mammography, it may lead to the inaccurate extraction of the tumor or breast tissue sample from the patient. Hence, such factors are fuelling the growth of this segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The prevalence of cancer has increased in North America. Cancer is the most common disease found in the population in this region. The region has been witnessing an increase in the adoption of various advanced technologies over the past few years. The majority of the market growth in this region is driven by high technology adoption in the healthcare sector, increasing healthcare expenditure, rising prevalence of breast cancer, and growing awareness among patients about mammograms to identify breast cancer incidence. Hence, such factors are driving the market in North America during the forecast period.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Medical conferences serve as pivotal platforms for discussing breakthrough techniques in cancer care, particularly in needle biopsies and the detection of DNA fragments indicative of early cancer stages. These gatherings facilitate dialogue on the complexity of tumors and advancements in clinical trials, leveraging the expertise of skilled surgeons and healthcare professionals. Tools such as biopsy tables, localization wires, and assay kits are instrumental in enhancing biopsy accuracy and supporting treatment monitoring and recurrence monitoring. Concerns over needle reuse underscore the importance of stringent protocols in biopsy procedures to mitigate risks and ensure patient safety. As research progresses, innovative techniques in needle biopsies are poised to revolutionize early cancer detection and personalized treatment strategies. Collaborative efforts across medical disciplines and industries are pivotal in driving these advancements forward, aiming to improve outcomes for patients navigating the complexities of cancer diagnosis and care. The conference highlighted a breakthrough technique in needle breast biopsies, promising advancements in early cancer detection.
Market Scope |
|
Report Coverage |
Details |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.87% |
Market growth 2024-2028 |
USD 778.7 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
9.53 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 36% |
Key countries |
US, Germany, France, China, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Advin Health Care, Allengers Medical Systems Ltd., Argon Medical Devices Inc., Becton Dickinson and Co., BIOPSYBELL Srl, Carestream Health Inc., Cook Group Inc., Danaher Corp., FUJIFILM Corp., General Electric Co., Hologic Inc., IZI Medical Products, Merit Medical Systems Inc., Metaltronica Spa, Planmed Oy, Scion Medical Technologies LLC, Siemens Healthineers AG, Suretech Medical Inc., Vector Medical, and Zamar Care |
Market dynamics |
Parent market analysis, Market forecasting growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by End-user
8 Market Segmentation by Modality
9 Customer Landscape
10 Geographic Landscape
11 Drivers, Challenges, and Opportunity/Restraints
12 Competitive Landscape
13 Competitive Analysis
14 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.